2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 04:09, 11 December 2023
, 11 December 2023→MIB-626
| Line 82: | Line 82: | ||
=== MIB-626 === | === MIB-626 === | ||
MIB-626, developed by MetroBiotech, is a microcrystalline form of NMN. This formulation may offer enhanced stability, solubility, or bioavailability compared to the regular crystalline form of NMN, potentially optimizing the efficacy of NMN supplementation. MetroBiotech plans to bring MIB-626 on the market as drug, not as dietary supplement. For that reason, several clinical trials are ongoing evaluating the effects and safety of MIB-626 on humans. Early results have indicated that a dosage of 1000 mg over 10 days can raise NAD+ levels about two-fold, and dosages as high as 2000 mg can triple the amount. | MIB-626, developed by MetroBiotech, is a microcrystalline form of NMN. This formulation may offer enhanced stability, solubility, or bioavailability compared to the regular crystalline form of NMN, potentially optimizing the efficacy of NMN supplementation. MetroBiotech plans to bring MIB-626 on the market as drug, not as dietary supplement. For that reason, several clinical trials are ongoing evaluating the effects and safety of MIB-626 on humans. Early results have indicated that a dosage of 1000 mg over 10 days can raise NAD+ levels about two-fold, and dosages as high as 2000 mg can triple the amount. | ||
[[File:MIB-626 NAD+ .png|thumb]] | |||
===Reduced NMN (NMNH)=== | ===Reduced NMN (NMNH)=== | ||